Wavefront-guided LASIK: a safe treatment for myopia & astigmatism

Article

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism.

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism, according to a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Simon R. Bababeygya and co-workers from Stanford University School of Medicine, Stanford, California, USA conducted a retrospective study which included 89 eyes of 45 patients with moderate (-6.0 to -8.0 D) and high (>-8.00 D) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO). All eyes were analyzed preoperatively and one, three, and 12 months postoperatively.

Mean age was 38.4 years ±7.14 (SD) and no eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10±0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33±0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within ±1.00 D of the intended correction and 64% were within ±0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.

The results of the study confirm that the correction of moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK is both safe and effective.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.